Please login to the form below

Not currently logged in
Email:
Password:

polycythemia vera

This page shows the latest polycythemia vera news and features for those working in and with pharma, biotech and healthcare.

Another R&D flop for Incyte, but Jakafi keeps delivering

Another R&D flop for Incyte, but Jakafi keeps delivering

Jakafi is marketed by Incyte in the US and by Novartis (as Jakavi) in other markets, for polycythemia vera and myelofibrosis.

Latest news

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    and polycythemia vera, both rare bone marrow cancers.  Celgene will pay approximately $1.1bn upfront for Impact and further contingent payments based on regulatory approval for fedratinib in myelofibrosis and other ... Acquisition company

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics